Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04340258 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion date: Sep 4, 2025 to Sep 4, 2026v7
  2. Primary completion date changed from estimate of Feb 4, 2025 to Jun 3, 2025 Completion date: Feb 4, 2025 to Sep 4, 2025v6 Show 1 more changeShow less
    • Completion date: Feb 4, 2025 to Sep 4, 2025
  3. Trial status: Recruiting to Active, Not Recruiting Study sites: 3 to 2v5 Show 1 more changeShow less
    • Study sites: 3 to 2
  4. Primary completion date: Feb 4, 2023 to Feb 4, 2025v4
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jun 1, 2022 to Feb 4, 2023 · Start date changed from estimate of Jun 1, 2020 to Feb 4, 2021 · Completion date: Jun 1, 2024 to Feb 4, 2025 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Jun 1, 2022 to Feb 4, 2023
    • Start date changed from estimate of Jun 1, 2020 to Feb 4, 2021
    • Completion date: Jun 1, 2024 to Feb 4, 2025
    • Site details revised at 3 of 3 sites
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To Study Perioperative PD-1 Inhibitor and Cesium-131 Interstitial Brachytherapy in patients with locally recurrent HNSCC eligible for salvage surgery.
Trial Details
NCT Number NCT04340258
Lead Sponsor University of Cincinnati
Collaborators: IsoRay Medical, Inc.
Conditions HNSCC
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov